Literature DB >> 16269352

Urotensin II: evidence for cardiac, hepatic and renal production.

Christopher J Charles1, Miriam T Rademaker, A Mark Richards, Timothy G Yandle.   

Abstract

Although urotensin II (UII) has been reported to circulate in human plasma and be raised in cardiovascular disorders, little, if any, information is available regarding the source of plasma UII. Accordingly, we have performed trans-organ arteriovenous sampling for measurement of UII concentration in anesthetized sheep. Plasma UII levels were measured in the low picomolar range in normal sheep and arterial plasma levels rose steadily with increasing time of anesthesia. Significant arteriovenous gradients were observed across the heart (36%), liver (40%) and kidney (44%). This is the first report to identify the heart, liver and kidney as sources of UII in the circulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269352     DOI: 10.1016/j.peptides.2005.03.043

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

Review 1.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

2.  Activation of a nerve injury transcriptional signature in airway-innervating sensory neurons after lipopolysaccharide-induced lung inflammation.

Authors:  Melanie Maya Kaelberer; Ana Isabel Caceres; Sven-Eric Jordt
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-11       Impact factor: 5.464

3.  Urotensin-II system in genetic control of blood pressure and renal function.

Authors:  Radoslaw Debiec; Paraskevi Christofidou; Matthew Denniff; Lisa D Bloomer; Pawel Bogdanski; Lukasz Wojnar; Katarzyna Musialik; Fadi J Charchar; John R Thompson; Dawn Waterworth; Kijoung Song; Peter Vollenweider; Gerard Waeber; Ewa Zukowska-Szczechowska; Nilesh J Samani; David Lambert; Maciej Tomaszewski
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

4.  The relationship between coronary slow flow phenomenon and urotensin-II: A prospective and controlled study.

Authors:  Halit Zengin; Ali Rıza Erbay; Ali Okuyucu; Hasan Alaçam; Serkan Yüksel; Murat Meriç; Korhan Soylu; Ömer Gedikli; Naci Murat; Okan Gülel; Sabri Demircan; Filiz Akın; Özcan Yılmaz; Mahmut Şahin
Journal:  Anatol J Cardiol       Date:  2014-04-28       Impact factor: 1.596

5.  Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.

Authors:  Anastasia Garoufi; Styliani Drapanioti; Antonios Marmarinos; Varvara Askiti; Andromachi J Mitsioni; Maria Mila; Georgia Grigoriadou; Dimitrios Georgakopoulos; Constantinos J Stefanidis; Dimitrios Gourgiotis
Journal:  BMC Nephrol       Date:  2017-03-31       Impact factor: 2.388

6.  The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population.

Authors:  Marko Simunovic; Andrija Jukic; Martina Paradzik; Daniela Supe-Domic; Lada Stanisic; Marina Degoricija; Anna Hummelvoll Hillestad; Veselin Skrabic; Josko Bozic
Journal:  Children (Basel)       Date:  2022-02-04

7.  Urotensin-II: More Than a Mediator for Kidney.

Authors:  Ayşe Balat; Mithat Büyükçelik
Journal:  Int J Nephrol       Date:  2012-10-10

Review 8.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.